| 前收市價 | 1,583.50 |
| 開市 | 1,579.50 |
| 買盤 | 1,538.00 x 0 |
| 賣出價 | 1,650.00 x 0 |
| 今日波幅 | 1,575.00 - 1,600.00 |
| 52 週波幅 | 1,302.60 - 1,725.81 |
| 成交量 | |
| 平均成交量 | 9,048,789 |
| 市值 | 65.336B |
| Beta 值 (5 年，每月) | 0.27 |
| 市盈率 (最近 12 個月) | 13.32 |
| 每股盈利 (最近 12 個月) | 1.20 |
| 業績公佈日 | 2024年5月01日 |
| 遠期股息及收益率 | 0.64 (4.04%) |
| 除息日 | 2024年2月22日 |
| 1 年預測目標價 | 無 |
Insider Monkey10 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]
ZacksGSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.
- Reuters
UPDATE 1-U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.
